Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 3 EP applications Andrew John Williams has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP15192658

2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

IPC classification:
A61K 31/437, A61K 31/506, A61P 35/00, C07D 401/02, C07D 471/04
Applicant:
AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca PLC
Status:
The patent has been granted
EP15700082

PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291

IPC classification:
A61K 9/20, A61K 31/506, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca PLC
Status:
EXAMINATION REQUESTED
EP15715805

COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER

IPC classification:
A61K 31/4184, A61K 31/506, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca PLC
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature